The production of the COVID-19 immunotherapy is part of a collaboration with the U.S. Food and Drug Administration, the National Institutes of Health, and the Biomedical Advanced Research Development Authority, among others. The drug will be produced in the company's Clayton, NC, facility which is specifically designed to process specialty immunoglobulins.

Immunoglobulins are plasma proteins that act like antibodies as part of the body's defense system. They have a broad scope of action including immunomodulatory effects. Immunoglobulins are used to treat autoimmune diseases and neurological conditions.

The first doses are expected to be available in July 2020 as part of a clinical trial in partnership with healthcare agencies, according to the company.

Thermo Fisher to develop, manufacture next-gen immunotherapy
Thermo Fisher Scientific has formed a strategic partnership with PharmAbcine for the development and manufacturing of PMC-309, a next-generation immune...

FDA researchers explore vaccine responses to SARS-CoV-2 antigens
Different proteins associated with SARS-CoV-2, the virus that causes COVID-19, generate unique immune responses when given to rabbits as immunizations,...

SARS-CoV mAb shown to block SARS-CoV-2
Antibodies from recovered SARS-CoV patients appear to block SARS-CoV-2 infectivity and could help in the development of antiviral treatments or vaccines,...

Scientists explore varying immune responses in COVID-19 patients
A new study aims to further classify the immune response of COVID-19 patients with the goal of understanding the pathogenesis of the disease and accelerating...

Experts discuss promising strategies for tackling SARS-CoV-2
What's the best strategy for developing treatments for the SARS-CoV-2 virus? The most promising approaches for a rapid response are antivirals and gene...